GLP-1RAs for craving reduction and relapse prevention in substance use disorders

Summaries 2 min 335

Font Size

Created On: 29/04/2026

Substance use disorders continue to pose a serious global health burden, marked by limited treatment options and high relapse rates.

See All

Key take away

GLP-1 receptor agonists reduce substance use, craving, and relapse behaviors by modulating brain reward pathways, showing promising potential in alleviating substance use disorders.

Background

Substance use disorders continue to pose a serious global health burden, marked by limited treatment options and high relapse rates. Recently, GLP-1 receptor agonists (GLP-1RAs)—widely employed in type 2 diabetes and obesity management—have emerged as promising candidates in addiction medicine.

Growing evidence suggests that GLP-1RAs influence brain reward pathways, particularly mesolimbic dopamine signaling, helping reduce craving, reward-seeking behavior, and substance dependence. Hence, this systematic review explored their potential role as novel pharmacological treatments for addiction.

Method

Researchers performed an extensive search across major databases, including PsycINFO, Cochrane Library, Web of Science, PubMed, and Embase. Eligible studies included both preclinical and clinical research evaluating GLP-1RAs in:

Alcohol use disorder
Nicotine addiction
Cocaine use disorder
Opioid dependence

Key data points included study design, patient characteristics, treatment interventions, substance use outcomes, and neurobiological mechanisms.

Result

A total of 41 studies were analyzed, including 35 preclinical and 6 clinical studies.

Reduced Substance Intake: GLP-1RAs such as exendin-4, liraglutide, and semaglutide lowered drug and alcohol consumption in preclinical studies.
Lower Relapse Risk: Evidence showed decreased relapse-like behaviors and cue-induced drug seeking across multiple substances.
Brain Mechanism: Effects were connected with GLP-1 receptor activity in critical reward regions, including ventral tegmental area, nucleus accumbens, and nucleus of the solitary tract.
Clinical Evidence: Early human trials, particularly in alcohol use disorder, illustrated reduced alcohol intake and craving with GLP-1RA therapy.

However, clinical data remain limited and inconsistent, largely owing to short trial durations and small sample sizes.

Conclusion

GLP-1RAs are a potential breakthrough in addiction treatment, offering a dual-action approach targeting both metabolic regulation and brain reward systems. While preclinical findings are robust, clinical evidence is still evolving. Larger, well-designed trials are fundamental to confirm potency.